Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021;124:1759–76.
Google Scholar
Jiang X, Xu J, Liu M, Xing H, Wang Z, Huang L, et al. Adoptive CD8+ T cell therapy against cancer: challenges and opportunities. Cancer Lett. 2019;462:23–32.
Google Scholar
Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2020;18:842–59.
Google Scholar
Zhao, Y, Deng, J, Rao, S, Guo, S, Shen, J, Du, F, et al. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers. 2022;14:4160.
Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ, et al. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021;16:25–36.
Google Scholar
Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat Biotechnol. 2020;38:448–59.
Google Scholar
Watanabe N, Mo F, McKenna MK. Impact of manufacturing procedures on CAR T cell functionality. Front Immunol 2022;13:876339.
Zhang DKY, Adu-Berchie K, Iyer S, Liu Y, Cieri N, Brockman JM, et al. Enhancing CAR-T cell functionality in a patient-specific manner. Nat Commun 2023;14(1):506.
Kouro, T, Himuro, H, Sasada, T Exhaustion of CAR T cells: potential causes and solutions. J Transl Med 2022;20:239.
Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S. CD8+ T cell exhaustion in cancer. Front Immunol. 2021;12:715234.
Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2021;22:209–23.
Google Scholar
Catakovic K, Klieser E, Neureiter D, Geisberger R. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Communication and Signaling. 2017;15:1.
Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T Cell dysfunction and exhaustion in cancer. Front Cell Dev Biol. 2020;8:17.
Zhu X, Li Q, Zhu X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front Cell Dev Biol. 2022;10:1034257.
Espie D, Donnadieu E. New insights into CAR T cell-mediated killing of tumor cells. Front Immunol. 2022;13:1016208.
Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, Mirarefin SMJ, Rahbarizadeh F. Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero? Front Immunol. 2022;13:795164.
Che Y, Yang Y, Suo J, An Y, Wang X. Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer. Cancer Immunol Immunother. 2020;69:2651–64.
Google Scholar
Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016;58:59–70.
Google Scholar
Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, et al. Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365:162–8.
Google Scholar
Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148–3165.e20.
Google Scholar
Gartlan KH, Belz GT, Tarrant JM, Minigo G, Katsara M, Sheng KC, et al. A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity. J Immunol. 2010;185:3158–66.
Google Scholar
Garcia-Mayea Y, Mir C, Carballo L, Sánchez-García A, Bataller M, LLeonart ME. TSPAN1, a novel tetraspanin member highly involved in carcinogenesis and chemoresistance. Biochimica et Biophysica Acta (BBA)—Rev Cancer. 2022;1877:188674.
Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6:801–11.
Google Scholar
Kummer D, Steinbacher T, Schwietzer MF, Thölmann S, Ebnet K. Tetraspanins: integrating cell surface receptors to functional microdomains in homeostasis and disease. Med Microbiol Immunol. 2020;209:397–405.
Google Scholar
Jiang X, Zhang J, Huang Y. Tetraspanins in cell migration. Cell Adhes Migr. 2015;9:406–15.
Google Scholar
Andreu Z, Yáñez-Mó M. Tetraspanins in extracellular vesicle formation and function. Front Immunol. 2014;5:442.
Lombardo SD, Mazzon E, Basile MS, Campo G, Corsico F, Presti M, et al. Modulation of tetraspanin 32 (TSPAN32) expression in T cell-mediated immune responses and in multiple sclerosis. Int J Mol Sci. 2019;20, 4323.
Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, et al. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat Cancer. 2020;1:1153–66.
Google Scholar
Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33:153–65.
Google Scholar
Zhou X, Xing J, Tang X, Sheng X, Chi H, Zhan W. Interleukin-2 (IL-2) interacts with IL-2 receptor beta (IL-2Rβ): its potential to enhance the proliferation of CD4+ T lymphocytes in flounder (paralichthys olivaceus). Front Immunol. 2020;11:531785.
Perales MA, Anderson LD Jr, Jain T, Kenderian SS, Oluwole OO, et al. Role of CD19 chimeric antigen receptor t cells in second-line large B cell lymphoma: lessons from phase 3 trials. an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Transpl Cell Ther. 2022;28:546–59.
Google Scholar
Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985–1005.
Google Scholar
D’Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia. 2019;34:21–34.
Google Scholar
Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2019;17:147–67.
Google Scholar
Qiu Q, Sun Y, Yang L, Li Q, Feng Y, Li M, et al. TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN. Signal Transduction Targeted Therapy. 2023;8:90.
Gumber D, Wang LD. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. eBioMedicine. 2022;77:103941.
Marro BS, Zak J, Zavareh RB, Teijaro JR, Lairson LL, Oldstone MBA. Discovery of small molecules for the reversal of T cell exhaustion. Cell Rep. 2019;29:3293–3302.e3.
Google Scholar
Luo M, Gong W, Zhang Y, Li H, Ma D, Wu K, et al. New insights into the stemness of adoptively transferred T cells by γc family cytokines. Cell Commun Signal. 2023;21:347.
Chinen T, Kannan AK, Levine AG, Fan X, Klein U, Zheng Y, et al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol. 2016;17:1322–33.
Google Scholar
